Literature DB >> 7363533

The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

K J Hoffmann, C G Regårdh, M Aurell, M Ervik, L Jordö.   

Abstract

Plasma concentration and urinary excretion of total and 2 active metabolites of metoprolol have been studied in patients with varying degrees of renal impairment and in healthy subjects after intravenous and oral administration of 20 and 50 mg of 3H-metoprolol tartrate respectively. Renal clearance of total metabolites correlated directly with 51Cr-EDTA clearance (r = 0.95, p less than 0.001). A reduction of glomerular filtration rate (GFR) by 70 to 80% increased the elimination half-life of total metabolites and of the active metabolite alpha-hydroxymetoprolol about 3-fold. Significant accumulation was, however, only observed in the patients with a GFR of about 5 ml/min. Even in these patients, the contribution of alpha-hydroxymetoprolol to the beta-adrenoceptor blocking effect of metoprolol will be negligible. The second active metabolite studied is eliminated via biotransformation, and the urinary excretion as well as the plasma concentration of this metabolite were extremely low in comparison with those of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7363533     DOI: 10.2165/00003088-198005020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  20 in total

1.  Calculation of drug dosage regimens in patients with renal disease: a new nomographic method.

Authors:  P Spring
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-01

2.  Quantitative determination of metoprolol in plasma and urine by gas chromatography.

Authors:  M Ervik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 4.  Interrelationship between renal haemodynamics, drug kinetics and drug action.

Authors:  K L Duchin; R W Schrier
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

5.  Pharmacodynamics of propranolol in renal failure.

Authors:  F D Thompson; A M Joekes; D M Foulkes
Journal:  Br Med J       Date:  1972-05-20

6.  The pharmacokinetics of metoprolol and its metabolites in dialysis patients.

Authors:  K U Seiler; K J Schuster; G J Meyer; W Niedermayer; O Wassermann
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 7.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Metabolism of metoprolol in the rat in vitro and in vivo.

Authors:  A Arfwidsson; K O Borg; K J Hoffmann; I Skånberg
Journal:  Xenobiotica       Date:  1976-11       Impact factor: 1.908

9.  Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards.

Authors:  M Ervik; K J Hoffmann; K Kylberg-Hanssen
Journal:  Biomed Mass Spectrom       Date:  1981-07

10.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more
  22 in total

1.  Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.

Authors:  N Bodor; Y Oshiro; T Loftsson; M Katovich; W Caldwell
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

2.  Variability of beta-blocker pharmacokinetics in young volunteers.

Authors:  D B Jack; C P Quarterman; R Zaman; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 3.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 4.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

Review 5.  Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.

Authors:  M J Kendall
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

6.  Glomerular filtration rate and creatinine clearance.

Authors:  J P Kampmann; J M Hansen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

7.  Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man.

Authors:  J B Lecaillon; P Massias; J P Schoeller; F Abadie
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals.

Authors:  C G Regårdh; S Landahl; M Larsson; P Lundborg; B Steen; K J Hoffmann; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

10.  The pharmacokinetics of metoprolol and its metabolites in dialysis patients.

Authors:  K U Seiler; K J Schuster; G J Meyer; W Niedermayer; O Wassermann
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.